Kestra Medical plans sale of 3,980 common shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Kestra Medical Technologies, Ltd. has a planned sale of common stock reported on Form 144. The filing covers 3,980 shares of common stock to be sold through Merrill Lynch, with an indicated value of $90,560.62 and a date of July 30, 2026 on NASDAQ.
The securities to be sold arose from the vesting of performance share unit awards on July 17, 2026, which were granted as part of the issuer’s equity compensation plan.
Key Figures
Key Terms
Form 144 regulatory
equity compensation plan financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does Kestra Medical Technologies (KMTS) disclose in this Form 144?
AI-generated analysis. How Rhea-AI works. Not financial advice.